Evidence map›Paper›PMID 29614332›Full record

ArticleToxicology letters2018

New therapeutic approaches and novel alternatives for organophosphate toxicity.

Francine S Katz, Stevan Pecic, Laura Schneider, Zhengxiang Zhu, Ashley Hastings-Robinson, Michal Luzac, Joanne Macdonald, Donald W Landry, Milan N Stojanovic

Abstract read
In one paragraph

Article in Toxicology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase.Chemistry (Weinheim an der Bergstrasse, Germany) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Francine S KatzDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA. Electronic address: fk2245@cumc.columbia.edu.
Stevan PecicDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA. Electronic address: sp2971@cumc.columbia.edu.
Laura SchneiderDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Zhengxiang ZhuDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Ashley Hastings-RobinsonDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Michal LuzacDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Joanne MacdonaldGenecology Research Centre, Inflammation and Healing Research Cluster, School of Science and Engineering, University of the Sunshine Coast, 90 Sippy Downs Drive Sippy Downs, QLD 4556, Australia.
Donald W LandryDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Milan N StojanovicDepartment of Medicine, Columbia University, 630 W 168th Street, BB8-444, New York, NY, 10032, USA.
Columbia University · USUniversity of the Sunshine Coast · AU

Funding

Development of amodiaquine and its analogs as reactivators of organophosphate-inhR21NS080790 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LANDRY, DONALD W · 2012 to 2013
$800k
UPLC Liquid Chromatograph Mass SpectrometerS10OD018121 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STOJANOVIC, MILAN N · 2014 to 2014
$160k
NIH HHS S10 OD018121NINDS NIH HHS R21 NS080790
6 · The paper itself

Abstract

Organophosphate compounds (OPCs) are commonly used as pesticides and were developed as nerve agents for chemical warfare. Exposure to OPCs results in toxicity due to their covalent binding and inhibition of acetylcholinesterase (AChE). Treatment for toxicity due to OPC exposure has been largely focused on the reactivation of AChE by oxime-based compounds via direct nucleophilic attack on the phosphorous center. However, due to the disadvantages to existing oxime-based reactivators for treatment of OPC poisoning, we considered non-oxime mechanisms of reactivation. A high throughput screen of compound libraries was performed to discover previously unidentified reactivation compounds, followed by studies on their analogs. In the process, we discovered multiple non-oxime classes of compounds, the most robust of which we have already reported [1]. Herein, we report other classes of compounds we identified in our screen that are efficient at reactivation. During biochemical characterization, we also found some compounds with other activities that may inspire novel therapeutic approaches to OPC toxicity. Specifically, we found compounds that [1] increase the rate of substrate hydrolysis by AChE and, [2] protect the enzyme from inhibition by OPC. Further, we discovered that a subset of reactivator compounds recover activity from both AChE and the related enzyme butyrylcholinesterase (BuChE). We now report these compounds, their activities and discuss how each relates to therapeutic approaches that would provide alternatives to traditional oxime-based reactivation.

Indexed as

AcetylcholinesteraseButyrylcholinesteraseCholinesterase InhibitorsCholinesterase ReactivatorsDonepezilHigh-Throughput Screening AssaysHumansHydrolysisImidazolesIndansKineticsOrganophosphate PoisoningOximesPiperazinesPiperidinesPyridinesAcetylcholinesteraseButyrylcholinesteraseCholinesterase InhibitorsCholinesterase ReactivatorsDonepezilImidazolesIndansOximesPiperazinesPiperidinesPyridinesAcetylcholinesterase (AChE)Butyrylcholinesterase (BuChE)Non-oxime reactivatorsOrganophosphate compounds (OPCs)Structure activity relationship (SAR) study

Identifiers

PMID29614332
PMCPMC5955786
OpenAlexW2795355969

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.